One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Rheumatoid arthritis, bone and drugs: a dangerous interweave
Salvatore Minisola, Jessica Pepe, Cristiana Cipriani
doi : 10.1136/annrheumdis-2020-219545
Annals of the Rheumatic Diseases 2021;80:409-410.
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
Johannes WJ Bijlsma
doi : 10.1136/annrheumdis-2020-219773
Annals of the Rheumatic Diseases 2021;80:411-412.
Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis
Wenhui Hu, Yueqi Chen, Ce Dou, Shiwu Dong
doi : 10.1136/annrheumdis-2020-218089
Annals of the Rheumatic Diseases 2021;80:413-422.
Osteoarthritis (OA) is a degenerative joint disease in the elderly. Although OA has been considered as primarily a disease of the articular cartilage, the participation of subchondral bone in the pathogenesis of OA has attracted increasing attention. This review summarises the microstructural and histopathological changes in subchondral bone during OA progression that are due, at the cellular level, to changes in the interactions among osteocytes, osteoblasts, osteoclasts (OCs), endothelial cells and sensory neurons. Therefore, we focus on how pathological cellular interactions in the subchondral bone microenvironment promote subchondral bone destruction at different stages of OA progression. In addition, the limited amount of research on the communication between OCs in subchondral bone and chondrocytes (CCs) in articular cartilage during OA progression is reviewed. We propose the concept of ‘OC–CC crosstalk’ and describe the various pathways by which the two cell types might interact. Based on the ‘OC–CC crosstalk’, we elaborate potential therapeutic strategies for the treatment of OA, including restoring abnormal subchondral bone remodelling and blocking the bridge—subchondral type H vessels. Finally, the review summarises the current understanding of how the subchondral bone microenvironment is related to OA pain and describes potential interventions to reduce OA pain by targeting the subchondral bone microenvironment.
Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study
Shahab Abtahi, Johanna H M Driessen, Andrea M Burden, Patrick C Souverein, Joop P van den Bergh, Tjeerd P van Staa, Annelies Boonen, Frank de Vries
doi : 10.1136/annrheumdis-2020-218758
Annals of the Rheumatic Diseases 2021;80:423-431.
Background Patients with rheumatoid arthritis (RA) commonly use oral glucocorticoids (GCs) and proton pump inhibitors (PPIs), both associated with osteoporotic fractures. We investigated the association between concomitant use of oral GCs and PPIs and the risk of osteoporotic fractures among patients with RA.
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Roy M Fleischmann, Ricardo Blanco, Stephen Hall, Glen T D Thomson, Filip E Van den Bosch, Cristiano Zerbini, Louis Bessette, Jeffrey Enejosa, Yihan Li, Yanna Song, Ryan DeMasi, In-Ho Song
doi : 10.1136/annrheumdis-2020-218412
Annals of the Rheumatic Diseases 2021;80:432-439.
Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy.
Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis
Haruka Tsuchiya, Mineto Ota, Shuji Sumitomo, Kazuyoshi Ishigaki, Akari Suzuki, Toyonori Sakata, Yumi Tsuchida, Hiroshi Inui, Jun Hirose, Yuta Kochi, Yuho Kadono, Katsuhiko Shirahige, Sakae Tanaka, Kazuhiko Yamamoto, Keishi Fujio
doi : 10.1136/annrheumdis-2020-218189
Annals of the Rheumatic Diseases 2021;80:440-450.
Objectives Synovial fibroblasts (SFs) are one of the major components of the inflamed synovium in rheumatoid arthritis (RA). We aimed to gain insight into the pathogenic mechanisms of SFs through elucidating the genetic contribution to molecular regulatory networks under inflammatory condition.
Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis
Darja Andreev, Mengdan Liu, Katerina Kachler, Mireia Llerins Perez, Philipp Kirchner, Julia K?lle, Andreas Gie?l, Simon Rauber, Rui Song, Oliver Aust, Anika Grüneboom, Arnd Kleyer, Juan D Ca?ete, Arif Ekici, Andreas Ramming, Susetta Finotto, Georg Schett, Aline Bozec
doi : 10.1136/annrheumdis-2020-218902
Annals of the Rheumatic Diseases 2021;80:451-468.
Objectives Eosinophils possess pro-inflammatory functions in asthma. However, our recent studies have suggested that innate lymphoid cells type 2 (ILC2s) and eosinophils have proresolving properties in rheumatoid arthritis (RA). Nothing is known yet about the mechanisms determining the double-edged role of eosinophils. Therefore, we investigated whether asthma, a paradigm eosinophilic disease, can elicit resolution of chronic arthritis.
Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?
Xenofon Baraliakos, Adrian Richter, Daniel Feldmann, Anne Ott, Robin Buelow, Carsten O Schmidt, Juergen Braun
doi : 10.1136/annrheumdis-2020-218669
Annals of the Rheumatic Diseases 2021;80:469-474.
Objective Identify factors associated with presence and extension of spinal and sacroiliac joints (SIJ)–MRI lesions suggestive of axial spondyloarthritis (axSpA) in a population-based cohort (Study of Health in Pomerania) aged <45 years.
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
Silvia Menegatti, Vincent Guillemot, Eleonora Latis, Hanane Yahia-Cherbal, Daniela Mittermüller, Vincent Rouilly, Elena Mascia, Nicolas Rosine, Surya Koturan, Gael A Millot, Claire Leloup, Darragh Duffy, Aude Gleizes, Salima Hacein-Bey-Abina, Milieu Intérieur Consortium, Jérémie Sellam, Francis Berenbaum, Corinne Miceli-Richard, Maxime Dougados, Elisabetta Bianchi, Lars Rogge
doi : 10.1136/annrheumdis-2020-218304
Annals of the Rheumatic Diseases 2021;80:475-486.
Objectives Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not effective in all patients and the biological basis for treatment failure remains unknown. We have analysed induced immune responses to define the mechanism of action of TNF blockers in SpA and to identify immunological correlates of responsiveness to TNFi.
10-Year natural course of early hip osteoarthritis in middle-aged persons with hip pain: a CHECK study
Annemaria C. van Berkel, Dieuwke Schiphof, Jan H. Waarsing, Jos Runhaar, John M. van Ochten, Patrick J.E. Bindels, Sita M.A. Bierma-Zeinstra
doi : 10.1136/annrheumdis-2020-218625
Annals of the Rheumatic Diseases 2021;80:487-493.
Objective To explore the natural course of hip osteoarthritis (OA) in a population of first-time presenters with hip complaints.
Constitutional morphological features and risk of hip osteoarthritis: a case–control study using standard radiographs
Hunar Abdulrahim, Qiang Jiao, Subhashisa Swain, Khosrow Sehat, Aliya Sarmanova, Kenneth Muir, Weiya Zhang, Michael Doherty
doi : 10.1136/annrheumdis-2020-218739
Annals of the Rheumatic Diseases 2021;80:494-501.
Objectives To evaluate the risk of association with hip osteoarthritis (OA) of 14 morphological features measured on standard antero-posterior pelvis radiographs.
Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative
Michael A. Bowes, Katherine Kacena, Oras A. Alabas, Alan D. Brett, Bright Dube, Neil Bodick, Philip G Conaghan
doi : 10.1136/annrheumdis-2020-217160
Annals of the Rheumatic Diseases 2021;80:502-508.
Objectives Osteoarthritis (OA) structural status is imperfectly classified using radiographic assessment. Statistical shape modelling (SSM), a form of machine-learning, provides precise quantification of a characteristic 3D OA bone shape. We aimed to determine the benefits of this novel measure of OA status for assessing risks of clinically important outcomes.
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial
Paula Dakin, Alan J Kivitz, Joseph S Gimbel, Nebojsa Skrepnik, Stephen J DiMartino, Chetachi A Emeremni, Haitao Gao, Neil Stahl, David M Weinreich, George D Yancopoulos, Gregory P Geba
doi : 10.1136/annrheumdis-2020-217259
Annals of the Rheumatic Diseases 2021;80:509-517.
Objectives To study the efficacy and safety of fasinumab in moderate-to-severe, chronic low back pain (CLBP).
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries
Christian Dejaco, Alessia Alunno, Johannes WJ Bijlsma, Annelies Boonen, Bernard Combe, Axel Finckh, Pedro M Machado, Ivan Padjen, Francisca Sivera, Tanja A Stamm, Frank Buttgereit
doi : 10.1136/annrheumdis-2020-218697
Annals of the Rheumatic Diseases 2021;80:518-526.
Objectives To investigate how the first wave of COVID-19 pandemic influenced decisions of rheumatologists and health professionals in rheumatology regarding the management of patients with inflammatory rheumatic and musculoskeletal diseases (RMDs).
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors
doi : 10.1136/annrheumdis-2020-218310
Annals of the Rheumatic Diseases 2021;80:527-538.
Objectives There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with severe disease, then with death. We also compared mortality between patients hospitalised for COVID-19 with and without iRMD.
Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area
Rim Bourguiba, Marion Delplanque, Caroline Vinit, Felix Ackermann, Léa Savey, Gilles Grateau, Veronique Hentgen, Sophie Georgin-lavialle
doi : 10.1136/annrheumdis-2020-218707
Annals of the Rheumatic Diseases 2021;80:539-540.
Do autoantibody-responses mature between presentation with arthralgia suspicious for progression to rheumatoid arthritis and development of clinically apparent inflammatory arthritis? A longitudinal serological study
Fenne Wouters, Ellis Niemantsverdriet, Nazike Salioska, Annemarie L Dorjée, René E M Toes, Annette H M van der Helm-van Mil
doi : 10.1136/annrheumdis-2020-218221
Annals of the Rheumatic Diseases 2021;80:540-542.
Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation
Takehiko Mori, Masuho Saburi, Maki Hagihara, Masaaki Mori, Rie Yamazaki, Jun Kato
doi : 10.1136/annrheumdis-2020-218695
Annals of the Rheumatic Diseases 2021;80:542-543.
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
Yuchuan Ding, Baozhen Huang, Yuan Wang, Jun Hou, Ying Chi, Zhixuan Zhou, Jianguo Li
doi : 10.1136/annrheumdis-2020-218582
Annals of the Rheumatic Diseases 2021;80:543-545.
Impact of grouping serial journal articles by disease category: analysis of article placement order in ARD 2013–2019
Janine Hill, Nicola Dalbeth, Greg D Gamble, Andrew Grey, Sarah Stewart
doi : 10.1136/annrheumdis-2020-218358
Annals of the Rheumatic Diseases 2021;80:545-546.
Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
Luisa Costa, Marco Tasso, Nadia Scotti, Erika Mostacciuolo, Nicol? Girolimetto, Francesca Foglia, Antonio del Puente, Raffaele Scarpa, Francesco Caso
doi : 10.1136/annrheumdis-2020-217806
Annals of the Rheumatic Diseases 2021;80:e46.
Response to: ‘Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort’ by Costa et al
Latika Gupta, Durga Prasanna Misra, Vishwesh Agarwal, Suma Balan, Vikas Agarwal
doi : 10.1136/annrheumdis-2020-217953
Annals of the Rheumatic Diseases 2021;80:e47.
Telemedicine will not keep us apart in COVID-19 pandemic
Simone Perniola, Stefano Alivernini, Valentina Varriano, Annamaria Paglionico, Giacomo Tanti, Pietro Rubortone, Lucia Lanzo, Fabrizio Melpignano, Carlo Tur, Enrico De Lorenzis, Giusy Peluso, Annunziata Capacci, Elisa Gremese
doi : 10.1136/annrheumdis-2020-218022
Annals of the Rheumatic Diseases 2021;80:e48.
Response to: ‘Telemedicine will not keep us apart in the COVID-19 pandemic’ by Perniola et al
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
doi : 10.1136/annrheumdis-2020-218071
Annals of the Rheumatic Diseases 2021;80:e49.
COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases
Clementina L?pez-Medina, Alejandro Escudero, Eduardo Collantes-Estevez
doi : 10.1136/annrheumdis-2020-218008
Annals of the Rheumatic Diseases 2021;80:e50.
Response to: ‘COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases’ by Lopez-Medina et al
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
doi : 10.1136/annrheumdis-2020-218070
Annals of the Rheumatic Diseases 2021;80:e51.
Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
Marlene Plü?, Gamal Chehab, Peter Korsten
doi : 10.1136/annrheumdis-2020-217967
Annals of the Rheumatic Diseases 2021;80:e52.
Response to: ‘Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey’ by Plü? et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-218069
Annals of the Rheumatic Diseases 2021;80:e53.
Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
Lionel Carbillon, Amélie Benbara, Jeremy Boujenah
doi : 10.1136/annrheumdis-2020-217847
Annals of the Rheumatic Diseases 2021;80:e54.
Response to: ‘Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Carbillon et al
Maximilian F Konig, Milena Gianfrancesco, Jinoos Yazdany, Philip C Robinson
doi : 10.1136/annrheumdis-2020-217990
Annals of the Rheumatic Diseases 2021;80:e55.
Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak
Jan Holubar, Moglie Le Quintrec, Hind Letaief, Jean Luc Faillie, Yves-Marie Pers, Christian Jorgensen
doi : 10.1136/annrheumdis-2020-217919
Annals of the Rheumatic Diseases 2021;80:e56.
Response to: ‘Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak’ by Holubar et al
Alexis Mathian, Zahir Amoura
doi : 10.1136/annrheumdis-2020-217988
Annals of the Rheumatic Diseases 2021;80:e57.
Case series of acute arthritis during COVID-19 admission
Mar?a-del-Carmen L?pez-Gonz?lez, Maria Luisa Peral-Garrido, Irene Calabuig, Ernesto Tovar-Sugra?es, Vega Jovani, Pilar Bernabeu, Raquel Garc?a-Sevila, Jose-Manuel Le?n-Ram?rez, Oscar Moreno-Perez, Vicente Boix, Joan Gil, Esperanza Merino, Paloma Vela, Mariano Andrés
doi : 10.1136/annrheumdis-2020-217914
Annals of the Rheumatic Diseases 2021;80:e58
Response to: ‘Case series of acute arthritis in COVID-19 admission’ by L?pez-Gonz?lez et al
Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks
doi : 10.1136/annrheumdis-2020-217989
Annals of the Rheumatic Diseases 2021;80:e59.
Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic
George E Fragoulis, Gerasimos Evangelatos, Aikaterini Arida, Vasiliki-Kalliopi Bournia, Kalliopi Fragiadaki, Anastasios Karamanakos, Evrydiki Kravvariti, Katerina Laskari, Stylianos Panopoulos, Maria Pappa, Maria G Tektonidou, Petros P Sfikakis
doi : 10.1136/annrheumdis-2020-217935
Annals of the Rheumatic Diseases 2021;80:e60.
Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al
Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
doi : 10.1136/annrheumdis-2020-217987
Annals of the Rheumatic Diseases 2021;80:e61.
